DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: The addition of Romidepsin to CHOP did not result in improved progression-free survival in untreated PTCL patients, but it did demonstrate effectiveness in the TFH subtype (6), aligning with our research findings.